Clinical trials: Type 2 Diabetes Risk
Type 2 Diabetes, Metabolic Syndrome
Clinical Study on the Effect of a Synbiotic on Body Fat Mass
In this trial the effect of a synbiotic consisting of the three different strains of Lactobacillus fermentum and acacia gum (gum arabic) on body fat mass, body weight, long-term glycemia, insulin resistance and other risk factors…
- Conditions
- Type 2 Diabetes, Metabolic Syndrome, Obesity, Abdominal, Obesity, Visceral
- Trial name
- NCT04754464
- Testing
- synbiotic, microcrystalline cellulose
- Where
- 2 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- Slimbiotics GmbH
Diabetes, Diabetes Mellitus, Type 2
Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes
This study is conducted in Asia. The aim of this study is to assess the efficacy of a pre-pregnancy life style intervention to reduce the risk of diabetes and prediabetes.
- Trial name
- Jom Mama (NCT02617693)
- Testing
- lifestyle intervention, standard antenatal care
- Where
- Malaysia
- Volunteers
- 552 people
- Sponsor
- Novo Nordisk A/S
Type II Diabetes Mellitus, Obesity
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
One out of two adults in Canada is currently overweight and therefore at increased risk for a number of medical conditions including diabetes, high blood pressure, heart attacks and stroke.
- Trial name
- NCT01644201
- Testing
- PolyGlycopleX® - PGX®
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- InovoBiologic Inc.
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial…
- Conditions
- Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
- Trial name
- ORION-1 (NCT02597127)
- Testing
- ALN-PCSSC, Normal Saline
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 501 people
- Sponsor
- The Medicines Company
Diabetes Mellitus, Type 2
Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
The purpose of this study is to compare the incidence of hospitalization with acute liver failure among patients with type 2 diabetes who are new users of Saxagliptin and those who are new users of other oral antidiabetic drugs.
- Trial name
- NCT01086293
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus.
- Trial name
- PICT2RE (NCT03797885)
- Testing
- No treatment given
- Where
- 14 sites in Portugal
- Volunteers
- 730 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with…
- Trial name
- NCT01243424
- Testing
- linagliptin, glimepiride
- Where
- 613 sites in United States, Argentina and 41 more
- Volunteers
- 6,103 people
- Sponsor
- Boehringer Ingelheim
Acute Kidney Injury
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
To compare, by insulin use at the index date, the incidence of hospitalization for acute kidney injury (AKI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695082
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 539,310 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2, Kidney Disease, Chronic
A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)
This randomized, double-blind, placebo-controlled study will evaluate the potential of aleglitazar to reduce the risk of end stage renal disease and cardiovascular mortality in patients with type 2 diabetes mellitus and chronic…
- Trial name
- NCT01893242
- Testing
- Aleglitazar
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2, Diabetic Foot
Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure
The goal of this clinical investigation is to explore a non-invasive technology for measuring the microcirculatory structure, composition and function in patients from a primary care population. The main aims are: 1.
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Foot, Peripheral Arterial Disease, Skin Cancer
- Trial name
- Spectrum1 (NCT06976073)
- Where
- 3 sites in Sweden
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- HJN Sverige AB/Neko Health
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Acute Coronary Syndrome, Type 2 Diabetes
A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)
The purpose of this study is to determine the safety and feasibility of BXT-51072 as a cardioprotective agent in diabetics undergoing elective angioplasty / percutaneous intervention (PCI), a procedure to "open" coronary…
- Trial name
- NCT00320502
- Testing
- BXT-51072
- Where
- 4 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Synvista Therapeutics, Inc
Fractures, Bone, Type II Diabetes
Fracture Risk With Thiazolidinediones
Treatment with thiazolidinediones (TZD) has recently been reported to possibly increase the risk of fractures in a randomized trial exploring the efficacy of rosiglitazone (RSG), metformin, or glyburide encompassing 4360 patients…
- Trial name
- NCT01055223
- Testing
- TZD only (RSG or PIO or troglitazone), TZD + spironolactone, TZD + amiloride
- Volunteers
- 98,483 people
- Sponsor
- GlaxoSmithKline
Malnutrition, Diabetes
Oral Nutritional Supplement in Type 2 Diabetes Subjects With or at Risk of Malnutrition
This multicenter, prospective study will evaluate the use of a nutritional support program including an oral diabetes-specific nutritional supplement consumed twice a day on the nutritional status of patients with T2D with or at…
- Trial name
- NCT05913193
- Testing
- Oral Nutritional Supplement (ONS)
- Where
- 17 sites in Spain
- Volunteers
- 231 people
- Sponsor
- Abbott Nutrition
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
Primary Objectives: To assess efficacy in terms of change from baseline in Hemoglobin A1c (HbA1c) at the end of study between the two drugs.
- Trial name
- ACADEMIC (NCT03794336)
- Testing
- Alogliptin, Acarbose, Metformin
- Where
- China
- Volunteers
- 1,293 people
- Sponsor
- Sanofi
Type 2 Diabetes, Cardiovascular Risk
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already…
- Trial name
- AMBITION 7 (NCT07797335)
- Testing
- Zenagamtide, Insulin glargine U-100
- Where
- 330 sites in United States, Argentina and 14 more
- Volunteers
- 1,778 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Obesity
Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study
This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Chronic Kidney Disease, Cardiovascular Risk
- Trial name
- NCT07673822
- Testing
- No treatment given
- Where
- South Korea
- Volunteers
- 800,000 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or…
- Trial name
- DECLARE-TIMI58 (NCT01730534)
- Testing
- Dapagliflozin 10 mg
- Where
- 805 sites in United States, Argentina and 32 more
- Volunteers
- 17,190 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation.
- Trial name
- NCT03492580
- Testing
- Canagliflozin, Empagliflozin, Dapagliflozin
- Where
- United States
- Volunteers
- 714,582 people
- Sponsor
- Janssen Research & Development, LLC